[go: up one dir, main page]

IL147488A0 - Glial derived neurotrophic factor - Google Patents

Glial derived neurotrophic factor

Info

Publication number
IL147488A0
IL147488A0 IL14748802A IL14748802A IL147488A0 IL 147488 A0 IL147488 A0 IL 147488A0 IL 14748802 A IL14748802 A IL 14748802A IL 14748802 A IL14748802 A IL 14748802A IL 147488 A0 IL147488 A0 IL 147488A0
Authority
IL
Israel
Prior art keywords
gdnf
neurotrophic factor
derived neurotrophic
glial derived
vector
Prior art date
Application number
IL14748802A
Other languages
English (en)
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Priority to IL14748802A priority Critical patent/IL147488A0/xx
Publication of IL147488A0 publication Critical patent/IL147488A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
IL14748802A 1991-09-20 2002-01-06 Glial derived neurotrophic factor IL147488A0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL14748802A IL147488A0 (en) 1991-09-20 2002-01-06 Glial derived neurotrophic factor

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US76468591A 1991-09-20 1991-09-20
US77410991A 1991-10-08 1991-10-08
US78842391A 1991-11-06 1991-11-06
US85541392A 1992-03-19 1992-03-19
IL10322392A IL103223A (en) 1991-09-20 1992-09-18 Glial-cell derived neurotrophic factor (gdnf), nucleic acid molecules encoding gdnf and methods and compositions for their use
IL14748802A IL147488A0 (en) 1991-09-20 2002-01-06 Glial derived neurotrophic factor

Publications (1)

Publication Number Publication Date
IL147488A0 true IL147488A0 (en) 2002-08-14

Family

ID=27505700

Family Applications (5)

Application Number Title Priority Date Filing Date
IL10322392A IL103223A (en) 1991-09-20 1992-09-18 Glial-cell derived neurotrophic factor (gdnf), nucleic acid molecules encoding gdnf and methods and compositions for their use
IL12191397A IL121913A0 (en) 1991-09-20 1997-10-07 Glial derived neurotrophic factor
IL14065400A IL140654A0 (en) 1991-09-20 2000-12-31 Glial cell line-derived neurotrophic factor antibody
IL14065300A IL140653A0 (en) 1991-09-20 2000-12-31 Glial cell line-derived neurotrophic factor antibody
IL14748802A IL147488A0 (en) 1991-09-20 2002-01-06 Glial derived neurotrophic factor

Family Applications Before (4)

Application Number Title Priority Date Filing Date
IL10322392A IL103223A (en) 1991-09-20 1992-09-18 Glial-cell derived neurotrophic factor (gdnf), nucleic acid molecules encoding gdnf and methods and compositions for their use
IL12191397A IL121913A0 (en) 1991-09-20 1997-10-07 Glial derived neurotrophic factor
IL14065400A IL140654A0 (en) 1991-09-20 2000-12-31 Glial cell line-derived neurotrophic factor antibody
IL14065300A IL140653A0 (en) 1991-09-20 2000-12-31 Glial cell line-derived neurotrophic factor antibody

Country Status (21)

Country Link
US (7) US7226758B1 (xx)
EP (2) EP0610254B1 (xx)
KR (1) KR100242093B1 (xx)
AT (1) ATE275197T1 (xx)
AU (2) AU679167B2 (xx)
CA (1) CA2119463C (xx)
DE (1) DE69233407T2 (xx)
DK (1) DK0610254T3 (xx)
ES (1) ES2225819T3 (xx)
FI (1) FI117556B (xx)
GE (1) GEP20002243B (xx)
HK (1) HK1047438A1 (xx)
HU (2) HU220795B1 (xx)
IL (5) IL103223A (xx)
MX (1) MX9205293A (xx)
NO (1) NO321382B1 (xx)
NZ (1) NZ244392A (xx)
PT (1) PT100879B (xx)
SG (1) SG48145A1 (xx)
TW (1) TW401422B (xx)
WO (1) WO1993006116A1 (xx)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
CA2170751A1 (en) * 1993-09-01 1995-03-09 Timothy J. Cunningham Neuron regulatory factor for promoting neuron survival
WO1995017203A1 (en) * 1993-12-22 1995-06-29 The University Of Medicine And Dentistry Of New Jersey Novel nucleic acid sequences isolated from glial cells
ES2276393T3 (es) * 1994-04-25 2007-06-16 Genentech, Inc. Cardiotrofina y sus usos.
US7258983B2 (en) 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US5853385A (en) * 1994-08-26 1998-12-29 Cytotherapeutics, Inc. Encapsulated PC12 cell transplants for treatment of Parkinson's disease
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
JP3093974B2 (ja) * 1995-06-27 2000-10-03 住友ベークライト株式会社 神経細胞用培養液、その製造方法及びこれを用いる神経細胞の培養方法
US6743628B1 (en) 1995-08-28 2004-06-01 Washington University Method of cell culture using neurturin
US5739307A (en) * 1995-08-28 1998-04-14 Washington University Polynucleotide encoding neurturin neurotrophic factor
US6184200B1 (en) 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
AU1121997A (en) * 1995-11-29 1997-06-19 Amgen, Inc. Method for treating sensory neuropathy using glial cell line-derived neurotrophic factor (gdnf) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US5929041A (en) * 1996-02-23 1999-07-27 Amgen Inc. Method for preventing and treating sensorineural hearing loss and vestibular disorders using glial cell line-derived neurotrophic factor(GDNF) protein product
US5837681A (en) * 1996-02-23 1998-11-17 Amgen Inc. Method for treating sensorineural hearing loss using glial cell line-derived neurotrophic factor (GDNF) protein product
PT888385E (pt) 1996-03-14 2004-01-30 Genentech Inc Utilizacoes de gdnf e de receptores de gdnf
US6222022B1 (en) * 1996-03-14 2001-04-24 Washington University Persephin and related growth factors
US6716600B1 (en) 1996-03-14 2004-04-06 Washington University Persephin and related growth factors
AU716846B2 (en) 1996-03-14 2000-03-09 Washington University Persephin and related growth factors
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6455277B1 (en) 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US7138251B1 (en) 1996-04-22 2006-11-21 Amgen Inc. Polynucleotides encoding a neurotrophic factor receptor
WO1997039629A1 (en) * 1996-04-25 1997-10-30 Genetic Therapy, Inc. Viral vectors including polynucleotides encoding neurotrophic factors and uses therefor
JP2000516457A (ja) * 1996-07-29 2000-12-12 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー ドパミン作動性ニューロンに対し生存促進活性を有するクロマフィン粒由来のｅｇｆ様因子および膠細胞由来の神経栄養因子
ATE397061T1 (de) * 1997-01-08 2008-06-15 Invitrogen Corp Verfahren zur herstellung von proteinen
US6025157A (en) 1997-02-18 2000-02-15 Genentech, Inc. Neurturin receptor
US6372453B1 (en) 1997-02-18 2002-04-16 Genetech, Inc. Neurturin receptor
US6777196B2 (en) 1997-02-18 2004-08-17 Genentech, Inc. Neurturin receptor
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
US6043221A (en) * 1997-07-30 2000-03-28 Amgen Inc. Method for preventing and treating hearing loss using a neuturin protein product
SI1005358T1 (en) * 1997-07-30 2003-06-30 Amgen Inc. Use of a neurturin protein product for preventing and treating hearing loss
AU737944B2 (en) * 1997-08-05 2001-09-06 F. Hoffmann-La Roche Ag Human glial cell line-derived neurotrophic factor promoters, vectors containing same, and methods of screening compounds therewith
DK1064376T3 (da) 1998-03-23 2006-07-24 Genentech Inc GFR-alpha3 og dets anvendelser
US7026138B1 (en) 1998-03-23 2006-04-11 Genentech, Inc. Polynucleotides encoding GFRα3
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US6593133B1 (en) 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US6426065B1 (en) * 2000-11-07 2002-07-30 Clairol Incorporated Use of tris(hydroxymethyl)aminomethane in cold permanent waving processes
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CN1525866B (zh) 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
US20030050273A1 (en) * 2001-08-29 2003-03-13 Keiya Ozawa Compositions and methods for treating neurodegenerative diseases
US8364229B2 (en) 2003-07-25 2013-01-29 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
US7613491B2 (en) 2002-05-22 2009-11-03 Dexcom, Inc. Silicone based membranes for use in implantable glucose sensors
US20030228295A1 (en) * 2002-04-25 2003-12-11 Svendsen Clive N. Use of human neural stem cells secreting GDNF for treatment of parkinson's and other neurodegenerative diseases
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7528112B2 (en) 2002-11-15 2009-05-05 Drexel University Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
WO2006002283A1 (en) * 2004-06-21 2006-01-05 Medtronic, Inc. Medical systems and methods for delivering compositions to cells
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
EP1587545A2 (en) * 2003-01-13 2005-10-26 Mahendra S. Rao Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US20050048041A1 (en) * 2003-01-13 2005-03-03 Rao Mahendra S. Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
ATE433759T1 (de) 2003-04-18 2009-07-15 Biogen Idec Inc Polymerkonjugiertes glycosiliertes neublastin
US7875293B2 (en) * 2003-05-21 2011-01-25 Dexcom, Inc. Biointerface membranes incorporating bioactive agents
ATE478092T1 (de) 2003-06-10 2010-09-15 Nsgene As Verbesserte sekretion von neublastin
US9763609B2 (en) 2003-07-25 2017-09-19 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
WO2005011520A2 (en) * 2003-07-25 2005-02-10 Dexcom, Inc. Oxygen enhancing membrane systems for implantable devices
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
US9135402B2 (en) 2007-12-17 2015-09-15 Dexcom, Inc. Systems and methods for processing sensor data
US7920906B2 (en) 2005-03-10 2011-04-05 Dexcom, Inc. System and methods for processing analyte sensor data for sensor calibration
US20050049196A1 (en) * 2003-08-29 2005-03-03 Michael Hutchinson Indirect delivery of growth factors into the central nervous system
US20060258576A1 (en) * 2003-09-05 2006-11-16 Licentia, Ltd Gdnf-related neuropeptides
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
US20060239966A1 (en) * 2003-10-20 2006-10-26 Tornoee Jens In vivo gene therapy of parkinson's disease
US9247900B2 (en) 2004-07-13 2016-02-02 Dexcom, Inc. Analyte sensor
US20050123526A1 (en) * 2003-12-01 2005-06-09 Medtronic Inc. Administration of growth factors for neurogenesis and gliagenesis
US8093205B2 (en) 2003-12-01 2012-01-10 Medtronic, Inc. Method for treating a stroke by implanting a first therapy delivery element in the CNS and a second therapy delivery element in a damaged tissue of the CNS to promote neurogenesis
WO2005079257A2 (en) * 2004-02-12 2005-09-01 Dexcom, Inc. Biointerface with macro- and micro- architecture
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
GB2414934A (en) * 2004-06-11 2005-12-14 Gill Steven Streatfield Treatment of Parkinson's disease with GDNF
US7946984B2 (en) 2004-07-13 2011-05-24 Dexcom, Inc. Transcutaneous analyte sensor
BRPI0514409A (pt) 2004-08-19 2008-06-10 Biogen Idec Inc redobra de proteìnas da famìlia de fator de crescimento transformante beta
ATE474586T1 (de) 2004-08-19 2010-08-15 Biogen Idec Inc Neublastin-varianten
US8133178B2 (en) 2006-02-22 2012-03-13 Dexcom, Inc. Analyte sensor
CN101287747A (zh) 2005-08-16 2008-10-15 哥本哈根大学 Gdnf衍生肽
US8053569B2 (en) * 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US8124095B2 (en) * 2005-10-07 2012-02-28 Armagen Technologies, Inc. Fusion proteins for delivery of erythropoietin to the CNS
US8741260B2 (en) * 2005-10-07 2014-06-03 Armagen Technologies, Inc. Fusion proteins for delivery of GDNF to the CNS
WO2007048413A1 (en) * 2005-10-28 2007-05-03 Nsgene A/S IMPLANTABLE BIOCOMPATIBLE IMMtTNOISOLATORY VEHICLE FOR DELIVERY OF GDNF
EP1969003B8 (en) * 2005-12-14 2010-11-10 Hermo Pharma Ltd. Uses of a NEUROTROPHIC FACTOR PROTEIN
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
WO2007120381A2 (en) * 2006-04-14 2007-10-25 Dexcom, Inc. Analyte sensor
ES2618787T5 (es) 2006-04-25 2022-10-21 Univ California Administración de factores de crecimiento para el tratamiento de trastornos del SNC
WO2007127839A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
EP1872790A1 (en) 2006-06-26 2008-01-02 DeveloGen Aktiengesellschaft New formulation for increasing bioavailability of neurturin
US8759297B2 (en) * 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
KR100770440B1 (ko) * 2006-08-29 2007-10-26 삼성전기주식회사 질화물 반도체 발광소자
US8637459B2 (en) 2006-11-08 2014-01-28 Emory University Enhancing a population of insulin releasing cells using GFR-A1 agonists
EP2142205B1 (en) 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
US20090011040A1 (en) * 2007-05-02 2009-01-08 Naash Muna I Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
US20200037875A1 (en) 2007-05-18 2020-02-06 Dexcom, Inc. Analyte sensors having a signal-to-noise ratio substantially unaffected by non-constant noise
WO2008157308A2 (en) * 2007-06-13 2008-12-24 Wayne State University Board Of Governors A zwitterion solution for low-volume therapeutic delivery
WO2008157288A2 (en) * 2007-06-13 2008-12-24 Wayne State University Board Of Governors A baclofen solution for low-volume therapeutic delivery
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
US9452258B2 (en) 2007-10-09 2016-09-27 Dexcom, Inc. Integrated insulin delivery system with continuous glucose sensor
US8417312B2 (en) 2007-10-25 2013-04-09 Dexcom, Inc. Systems and methods for processing sensor data
FI20070808A0 (fi) 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
US9839395B2 (en) 2007-12-17 2017-12-12 Dexcom, Inc. Systems and methods for processing sensor data
GB0803352D0 (en) * 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
EP3387993A3 (en) 2008-03-28 2018-11-14 Dexcom, Inc. Polymer membranes for continuous analyte sensors
FI20080326A0 (fi) 2008-04-30 2008-04-30 Licentia Oy Neurotroofinen tekijä MANF ja sen käytöt
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
WO2010093906A2 (en) 2009-02-12 2010-08-19 Curna, Inc. Treatment of glial cell derived neurotrophic factor (gdnf) related diseases by inhibition of natural antisense transcript to gdnf
WO2010108048A2 (en) 2009-03-18 2010-09-23 Armagen Technologies, Inc. Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
SI2485761T1 (sl) 2009-10-09 2019-05-31 Armagen, Inc. Postopki in sestavki za povečanje aktivnosti iduronat-2-sulfataze v CŽS
WO2011064437A2 (es) 2009-11-26 2011-06-03 Proyecto De Biomedicina Cima, S.L. Vectores virales y procedimientos útiles en la preparación de gdnf
DK2531206T3 (en) 2010-02-04 2017-09-11 Morphotek Inc CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USE THEREOF
ES2601182T3 (es) 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
US9149427B2 (en) 2010-12-02 2015-10-06 Neurotech Usa, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
UA112981C2 (uk) 2011-04-11 2016-11-25 Елі Ліллі Енд Компані Варіант людського gdnf
US20130053666A1 (en) 2011-08-26 2013-02-28 Dexcom, Inc. Polymer membranes for continuous analyte sensors
CA2857647C (en) 2011-12-02 2022-04-19 Armagen Technologies, Inc. Methods and compositions for increasing arylsulfatase a activity in the cns
US9788765B2 (en) 2012-09-28 2017-10-17 Dexcom, Inc. Zwitterion surface modifications for continuous sensors
US10156559B2 (en) 2012-12-10 2018-12-18 Fred Hutchinson Cancer Research Center Lipocalin fusion partners
EP2968462B1 (en) 2013-03-15 2020-12-23 The Jackson Laboratory Methods for promoting wound healing and hair growth
US9737250B2 (en) 2013-03-15 2017-08-22 Dexcom, Inc. Membrane for continuous analyte sensors
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10369329B2 (en) 2014-01-30 2019-08-06 Renishaw Plc Neurosurgical apparatus and method
EP3140429B1 (en) 2014-05-05 2020-02-19 Medtronic Inc. Methods for scd, crt, crt-d, or sca therapy identification and/or selection
US10538589B2 (en) 2015-01-14 2020-01-21 Armagen Inc. Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
GB201506052D0 (en) 2015-04-09 2015-05-27 Renishaw Plc Movement disorder
WO2016191645A1 (en) 2015-05-27 2016-12-01 Neurotech Usa, Inc. Use of encapsulated cell therapy for treatment of ophthalmic disorders
US20170188902A1 (en) 2015-12-30 2017-07-06 Dexcom, Inc. Enzyme immobilized adhesive layer for analyte sensors
WO2017181149A1 (en) 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer
CA3043179A1 (en) 2016-11-10 2018-05-17 Keros Therapeutics, Inc. Gdnf fusion polypeptides and methods of use thereof
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CA3210177A1 (en) 2021-03-19 2022-09-22 Dexcom, Inc. Drug releasing membrane for analyte sensor
EP4401634A1 (en) 2021-09-15 2024-07-24 Dexcom, Inc. Bioactive releasing membrane for analyte sensor
WO2023093905A1 (zh) 2021-11-29 2023-06-01 上海瑞宏迪医药有限公司 Aadc、gdnf多核苷酸及其用于治疗帕金森病
CA3228457A1 (en) 2022-02-02 2023-08-10 Dexcom, Inc. Sensing systems and methods for diagnosing, staging, treating, and assessing risks of liver disease using monitored analyte data
EP4482383A1 (en) 2022-02-23 2025-01-01 Dexcom, Inc. Sensing systems and methods for providing decision support around kidney health and/or diabetes
WO2023235442A1 (en) 2022-06-01 2023-12-07 Dexcom, Inc. Systems and methods for monitoring, diagnosis, and decision support for diabetes in patients with kidney disease
CN119730789A (zh) 2022-09-02 2025-03-28 德克斯康公司 连续分析物传感器设备和方法
WO2024145651A1 (en) 2022-12-30 2024-07-04 Dexcom, Inc. Sensing systems and methods for hybrid glucose and ketone monitoring
WO2024216297A1 (en) 2023-04-14 2024-10-17 Dexcom, Inc. Sensing systems and methods for providing optimized exercise guidance to metabolically unfit hosts using continuously monitored analyte data
AU2024249858A1 (en) 2023-04-14 2025-09-25 Dexcom, Inc. Sensing systems and methods for providing optimized exercise guidance to healthy hosts and athletes using continuously monitored analyte data
WO2025030070A1 (en) 2023-08-01 2025-02-06 Dexcom, Inc. Systems and methods for providing therapy management recommendations for diabetic patients and patients with liver disease
WO2025144778A1 (en) 2023-12-28 2025-07-03 Dexcom, Inc. Systems and methods for providing therapy management guidance related to liver disease decompensation to users with liver disease
US20250221642A1 (en) 2024-01-05 2025-07-10 Dexcom, Inc. Polymers with dual functionality

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DE3587022T2 (de) 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US5284763A (en) 1985-03-22 1994-02-08 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US4886747A (en) 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
US5089396A (en) 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5427780A (en) 1985-10-30 1995-06-27 Biogen, Inc. Composition comprising Mullerian inhibiting substance-like polypeptides
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) * 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE124726T1 (de) 1988-11-04 1995-07-15 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5017735A (en) 1989-07-24 1991-05-21 Catalytica, Inc. Selective sorption of 2,6-diisopropylnaphthalene
AU6174490A (en) 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
CA2064787A1 (en) * 1989-08-11 1991-02-12 Joe E. Springer Dopaminergic neurotrophic factor for treatment of parkinson's disease
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
WO1991010470A1 (en) 1990-01-08 1991-07-25 Brown University Research Foundation Devices and methods for enhanced delivery of active factors
US5270181A (en) 1991-02-06 1993-12-14 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin and thioredoxin-like molecules

Also Published As

Publication number Publication date
NZ244392A (en) 1995-03-28
ATE275197T1 (de) 2004-09-15
US6015572A (en) 2000-01-18
CA2119463C (en) 2003-09-16
HUT66137A (en) 1994-09-28
HU220795B1 (hu) 2002-05-28
US6093802A (en) 2000-07-25
WO1993006116A1 (en) 1993-04-01
IL103223A0 (en) 1993-02-21
US6362319B1 (en) 2002-03-26
IL103223A (en) 2005-06-19
TW401422B (en) 2000-08-11
PT100879B (pt) 1999-08-31
AU2681192A (en) 1993-04-27
DK0610254T3 (da) 2005-01-10
AU694387B2 (en) 1998-07-16
SG48145A1 (en) 1998-04-17
DE69233407D1 (de) 2004-10-07
HK1047438A1 (en) 2003-02-21
EP1243652A2 (en) 2002-09-25
EP0610254A4 (en) 1995-05-03
NO940922L (no) 1994-05-19
IL140653A0 (en) 2002-02-10
US7226758B1 (en) 2007-06-05
GEP20002243B (en) 2000-09-25
KR940702505A (ko) 1994-08-20
IL121913A0 (en) 1998-03-10
FI941285L (fi) 1994-03-18
HK1017816A1 (en) 1999-11-26
FI941285A0 (fi) 1994-03-18
HU211984A9 (en) 1996-01-29
IL140654A0 (en) 2002-02-10
MX9205293A (es) 1993-05-01
US5935795A (en) 1999-08-10
US20020197675A1 (en) 2002-12-26
EP0610254B1 (en) 2004-09-01
NO940922D0 (no) 1994-03-15
NO321382B1 (no) 2006-05-02
KR100242093B1 (ko) 2000-02-01
ES2225819T3 (es) 2005-03-16
EP0610254A1 (en) 1994-08-17
US6221376B1 (en) 2001-04-24
FI117556B (fi) 2006-11-30
HU9400717D0 (en) 1994-06-28
AU679167B2 (en) 1997-06-26
AU1900197A (en) 1997-09-18
PT100879A (pt) 1994-02-28
EP1243652A3 (en) 2003-03-26
DE69233407T2 (de) 2005-09-08
CA2119463A1 (en) 1993-04-01

Similar Documents

Publication Publication Date Title
HUT66137A (en) Glial derived neurotrophic factor
DE69229572D1 (de) Gliazellen-aktivierender Faktor und dessen Herstellung
AU4833897A (en) Glial mitogenic factors, their preparation and use
IL98205A0 (en) Type ii interleukin-1 receptors
CA2094027A1 (en) Osteogenic peptides
WO1998027204A3 (en) AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
IE801137L (en) Dna transfer vector
AU7869487A (en) Expression of biologically active factor XIII
CA2066618A1 (en) Plasmids containing dna encoding the amino acid sequence of tcf-ii, transformed cells with the plasmids, and production method of biologically active substance using the transformed cells
WO2000034474A3 (en) Growth factor homolog zvegf3
AU7681687A (en) Expression of platelet-derived growth factor and analogues
IE871871L (en) Cloning and expression of acidic fibroblast growth factor
CA2260365A1 (en) Differentiation-suppressive polypeptide
ATE346919T1 (de) Nebenhoden-spezifisches rezeptorprotein und dessen verwendung
AU7976487A (en) Production of recombinant human psti in saccharomyces cerevisiae
CA2324649A1 (en) Human p51 genes and gene products thereof
EP0322084A3 (en) Tumor cell inhibition factor
DK171489A (da) Peptidderivater
NZ333100A (en) Plant retinoblastoma-associated proteins and their use in modulating the cell cycle of a plant
허규정 Small GTP-binding Proteins
Clark et al. 4959455 Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
Brown et al. 4959353 Promotion of corneal stroma wound healing with human epidermal growth factor prepared from recombinant DNA
Baird et al. 4956455 Bovine fibroblast growth factor
ES2005114A6 (es) Procedimiento de producir factor de crecimiento de celulas endoteliales humano